Brief: Lupkynis® (Voclosporin) Achieved Significantly Higher Renal Response In Lupus Nephritis Patients With High Proteinuria Compared To Patients Treated With Mmf And Low Dose Steroids Alone
01/06/2023 14:04
June 1 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* LUPKYNIS® (VOCLOSPORIN) ACHIEVED SIGNIFICANTLY HIGHER
RENAL
RESPONSE IN LUPUS NEPHRITIS PATIENTS WITH HIGH PROTEINURIA
COMPARED TO PATIENTS TREATED WITH MMF AND LOW DOSE STEROIDS
ALONE
* AURINIA PHARMACEUTICALS INC - SIMILAR RATES OF AES WERE
REPORTED
IN BOTH ARMS AND MEAN EGFR LEVELS WERE SIMILAR AND STABLE OVER
ONE YEAR OF TREATMENT
Source text for Eikon: ID:nBw1ztJca
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death